Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor
Blood (2017) 130 (Supplement 1): 689.
Currently there are no citedby results. Try again later.
